Last week, the Centers for Medicare & Medicaid Services announced that beginning in fiscal year 2021 it will “no longer require new antimicrobial drugs that fight serious infections to meet the ‘substantial clinical improvement’ bar if they have already been designated as needed drugs, known as Qualified Infectious Disease Products, by the FDA.” In addition, the 2020 Hospital Inpatient Prospective Payment System (IPPS) Final Rule also increased add-on payments for these treatments from 50% to 75%. BARDA Director Rick Bright discusses the new rule and how it can improve the antimicrobial resistance (AMR) drug marketplace and re-catalyze innovation in basic science discovery, and research and development efforts.

NACCHO and ASPR Announce
Winners of 4th Annual
National Health Security Awards

BARDA and Industry Partner to Build a
Better Pipeline of Candidate Products
for Project BioShield

ASPR Ready: A New Opportunity to
Partner with Innovators to
Transform ASPR’s IT Systems

Resources to Help Healthcare
Planners Prepare for and Recover from
Post-disaster Utility Failures

DRIVe Partners with UC San Diego to
Develop Wearable that Provides
Continuous Monitoring of the
Vagus Nerve

Learn About the 200+
ASPR TRACIE Resources to
Help Enhance Disaster
Preparedness Response Planning

Active Shooter Situations Bring
Unique Challenges with a No-notice
Surge in Trauma Patients:
Learn How Your Healthcare Facility &
Community Can Prepare

Crossing the Finish Line:
Project BioShield is Transforming the
Nation’s Health Security with
Cutting-Edge Innovation, Sound
Investments, and Strong Partnerships